Integrins are transmembrane multi-conformation receptors that mediate interactions with the extracellular matrix. In cancer, integrins influence metastasis, proliferation, and survival. Collagen-binding integrin-α11/β1, a marker of aggressive tumors that is involved in stroma-tumor crosstalk, may be an attractive target for anti-cancer therapeutic antibodies. We performed selections with phage-displayed synthetic antibody libraries for binding to either purified integrin-α11/β1 or in situ on live cells. The insitu strategy yielded many diverse antibodies, and strikingly, most of these antibodies did not recognize purified integrin-α11/β1. Conversely, none of the antibodies selected for binding to purified integrin-α11/β1 were able to efficiently recognize native cell-surface antigen. Most importantly, only the in-situ selection yielded functional antibodies that were able to compete with collagen-I for binding to cellsurface integrin-α11/β1, and thus inhibited cell adhesion. In-depth characterization of a subset of in situderived clones as full-length immunoglobulins revealed high affinity cellular binding and inhibitory activities in the single-digit nanomolar range. Moreover, the antibodies showed high selectivity for integrin-α11/β1 with minimal cross-reactivity for close homologs. Taken together, our findings highlight the advantages of in-situ selections for generation of anti-integrin antibodies optimized for recognition and inhibition of native cell-surface proteins, and our work establishes general methods that could be extended to many other membrane proteins.
Introduction
Integrins are a family of heterodimeric transmembrane receptors that mediate cell-cell and cell-extracellular matrix (ECM) interactions. Integrins are associated with cell growth, division and differentiation, 1, 2 and they also interact with growth factors and cytokine receptors [3] [4] [5] [6] to affect cell survival pathways. [7] [8] [9] [10] Consequently, integrins play important roles in cancer biology by influencing tumor migration, proliferation and survival. 11, 12 Moreover, increased integrin expression in human tumors correlates with disease progression and reduced patient survival. [13] [14] [15] Thus, integrins are promising targets for cancer therapy.
A critical feature of the tumor microenvironment is the tumor-stroma interface, which relies on integrins that interact with ECM molecules and paracrine growth factors 11, 16, 17 to orchestrate proliferative cues, stimulate angiogenic pathways, and influence immuno-surveillance evasion mechanisms, [18] [19] [20] all of which are essential for tumor survival and progression. In particular, integrin-α11/β1 is upregulated in cancer-associated fibroblasts (CAFs) of metastatic tumors and behaves as a tumor-stroma mediator, [21] [22] [23] and its expression is correlated with aggressive tumors in patients24 Integrin-α11/β1 in CAFs interacts with collagen-I in the ECM to indirectly stimulate cancer-stromal stiffness and tumor progression through the release of factors that enhance tumor survival and growth. [25] [26] [27] [28] Accordingly, given its roles as a pro-tumorigenic factor and as a prognostic marker for metastatic tumors, integrin-α11/β1 shows potential as a cancer therapeutic target.
In recent years, antibodies (Abs) have risen to prominence as versatile tools for cancer research and also as therapeutics. [29] [30] [31] Indeed, a number of anti-integrin Abs are in clinical trials (ClinicalTrials.gov), including the following: anti-integrin-αV Abs for prostate cancer (NCT00537381), melanoma (NCT00246012), colorectal cancer (NCT01008475), and pancreatic cancer (NCT02683824); an anti-integrin-α5/β1 Ab for renal cell carcinoma (NCT00100685), melanoma (NCT00099970), lung cancer (NCT00654758), and pancreatic cancer (NCT00401570); and an anti-αV/β3 Ab for melanoma (NCT00111696) and lymphoma (NCT00111696). However, deriving selective and potent Abs against integrins remains challenging, because integrin heterodimers exist in multiple conformations 32, 33 that are difficult to recapitulate with purified recombinant proteins. Furthermore, integrin conformations are influenced by cations and the local membrane environment, 34 and they are exquisitely controlled by 'inside-out' signaling, [34] [35] [36] which may also augment dynamic conformational states and modulate their functions in the extracellular environment.
Given the dependence of integrin structure and function on the membrane environment, we applied a phage display strategy that enabled Ab selection in situ with native integrin-α11/β1 displayed on live cells. Utilizing this approach in combination with a highly functional phage-displayed synthetic Ab library, 37, 38 we demonstrated that in-situ selections yielded more diverse, potent and selective Abs than those obtained through conventional selections with purified recombinant integrin-α11/β1 protein. Moreover, some of the Abs identified from the in-situ selections acted as potent inhibitors of collagen-I binding to integrin-α11/β1 receptors on cells. Thus, these Abs will serve as valuable tools to interrogate integrin-α11/β1 function in cancer progression, and the general in-situ selection strategy can be applied to target other integrin family members and integral membrane proteins to identify promising cancer therapeutics.
Results

Selection and screening of anti-integrin-α11/β1 Abs
To assemble a diverse panel of anti-integrin-α11/β1 Abs, we used a highly functional library of antigen-binding fragments (Fabs) displayed on phage (library F) 37 and performed either conventional selections for binding to purified integrin-α11/β1 or in-situ selections with integrin-α11/β1 displayed on live cells. For the recombinant protein selections, we used the complete extra-cellular domains of integrin-α11 and integrin-β1 purified as a non-covalently linked heterodimer (see Materials & Methods for details). After four rounds of selection for binding to immobilized integrin-α11/β1, the screening of 96 individual phage clones by ELISA yielded eight unique Fabs (Figure 1a ).
For in-situ selections, we used two different cell lines engineered to overexpress integrin-α11/β1, CAF094-α11/β1 and C2C12-α11/β1 ( Fig. S1 ). To enable selection of diverse Abs, we confirmed previous reports of differential effects of Ca +2 , Mg +2 and Mn +2 cations on integrin conformation and function ( Fig. S2A-B ), and we performed separate selections with each of the two cell lines in the presence of each of these cations. We used a strategy whereby we first depleted clones that bound to other cell-surface antigens by exposing phage pools to control cells that did not express integrin-α11/β1, pelleting the cells, and collecting the supernatant containing the depleted phage pool. The depleted phage pool was then subjected to positive selections by incubating with CAF094-α11/β1 or C2C12-α11/β1 cells; the cells were pelleted and washed, and bound phage were eluted, amplified in E. coli and used for another round of selection ( Fig. S2C ).
After the fourth round, we isolated and analyzed 240 clones from each of the six selections (two different cell lines with three different cations) for specific binding to the cell line with which they were enriched. Thus, in total, we screened 1440 Fab-phage clones by cellular ELISA and identified 95 clones with sequences that were unique within their pool ( Fig. S2D ), each of which bound to immobilized CAF094-α11/β1 or C2C12-α11/β1 cells more strongly than to the parental cell line (data not shown). We then compared these 95 sequences to each other to consolidate any clones that were unique in one of the 6 pools, but were duplicates across pools, and this analysis yielded a final set of 82 unique sequences. From these 82 clones, Fab proteins were purified and evaluated by flow cytometry, yielding a set of 45 positive
Fabs that bound to both CAF094-α11/β1 and C2C12-α11/β1 cells, but did not bind to parental cell lines that did not express integrin-α11/β1 (Figure 1b and S3). The other 37 Fab proteins were deemed negative, as 23 did not bind selectively to either CAF094-α11/β1 or C2C12-α11/β1 cells and 14 bound selectively to C2C12-α11/β1 cells but not to CAF094-α11/β1 cells ( Fig. S3A ).
Identification of Abs that inhibit integrin-α11/β1 function
The entire panel of 53 anti-integrin-α11/β1 Fabs (Figure 1 ) was assessed for binding to purified integrin-α11/β1 by ELISA and cell-surface integrin-α11/β1 by flow cytometry (Figure 2a ). The eight Fabs from the conventional selection bound robustly to purified integrin-α11/β1, but did not exhibit significant binding to the cell-surface antigen. Conversely, the 45 Fabs from the insitu selection exhibited strong and selective binding to cells expressing integrin-α11/β1, but only a few exhibited even modest binding to purified integrin-α11/β1. We also screened the panel for their ability to inhibit the binding of integrin-α11/β1 to collagen-1 by assessing the effect of each Fab on the attachment of C2C12-α11/β1 cells to plates coated with collagen-1 ( Figure 2b ). As expected, the Fabs derived from the conventional selection, which did not recognize cell-surface integrin-α11/β1, were unable to inhibit cell attachment. Amongst the Fabs derived from the in-situ selections, a significant number were functional and nine strongly inhibited cell attachment (Figures 1b and 2b) . Notably, with the exception of A11-42, these inhibitory Fabs were among those that did not efficiently recognize purified integrin-α11/β1 ( Figure 1a ).
Next-generation sequencing analysis of cell-binding phage pools
We used next-generation sequencing (NGS) to comprehensively assess the sequences and abundances of the clones in each Fab-phage pool selected for binding to each integrin-α11/β1 overexpressing cell line under each cation condition, and also in pools selected for binding to negative control cell lines that did not overexpress integrin-α11/β1 ( Figure 3 ). Taking advantage of the simple library F design, which uses a single defined framework and contains diversity in only four complementary-determining regions (CDRs), we applied a sequencing strategy that recovered the complete paratope sequence for each clone (see Materials and Methods). Unique high-quality sequence reads from each pool were parsed based on CDR sequences and observation counts. The abundance of each unique paratope in each positive pool was plotted versus its enrichment in the positive pool relative to the negative pool ( Figure 3a ). To estimate the number of potential unique integrin-α11/β1-binding clones in each pool, we defined an upper-right quadrant of putative positives as those sequences representing more than 100 counts in the positive pool and being more than two-fold enriched relative to the negative pool. Notably, virtually all integrin-α11/β1-binding sequences validated by ELISA ( Figure 1 ) resided in this quadrant. We identified additional clones that were not validated by ELISA but are likely to bind integrin-α11/β1 given their location in the upper-right quadrant, and for each unique CDR L3 and H3 combination, we chose the clone with the highest counts in the positive pool as a representative of that paratope family.
In total, the selections in the presence of Mg +2 , Ca +2 or Mn +2 yielded 278, 277 or 122 unique putative integrin-α11/ β1-binding Abs, respectively ( Figure 3b ), and taken together, the cell-based selections yielded a total of 655 unique potential anti-integrin-α11/β1 Abs (Figure 3c ). Notably, there was very little overlap between the sequences enriched under the different selection conditions, suggesting that each individual selection did not capture all of the potential integrin-α11/ β1-binding clones in the naïve library. Consequently, additional more exhaustive selections utilizing larger quantities of Fab-phage and antigen-presenting cells would likely yield additional unique positive clones. Moreover, additional putative binders could be recovered by gene synthesis from the sequences identified by our NGS analysis, as the complete set Sequences of integrin-α11/β1 Abs. Abs were isolated by screening a phage-displayed Fab library for binding to (a) purified integrin-α11/β1 or (b) integrin-α11/β1 displayed on live cells. Sequences are shown for positions that were diversifed in the library and are numbered according to the IMGT nomenclature. 39 Dashes indicate gaps in the alignment. Underlined bold text indicates Abs that inhibited integrin-α11/β1 binding to collagen-1, and asterisks (*) indicate Abs that were also characterized as full-length immunoglobulins.
of 655 unique sequences is available ( Fig. S4 ). However, even the limited ELISA screen yielded numerous validated Fabs that could bind selectively to integrin-α11/β1 on cells, including a significant proportion that inhibited cell adhesion. Thus, we did not pursue the NGS data further, but rather focused our efforts on detailed characterization of inhibitory Abs.
Characterization of full-length anti-integrin-α11/β1 immunoglobulins
To assess the affinity, selectivity and potency of full-length immunoglobulins, we converted several Fabs into the human IgG1 format. As our main interest was to develop inhibitors of integrin-α11/β1 function, we chose six Fabs that strongly blocked adhesion of C2C12-α11/β1 cells to collagen-I ( Figure 2b) , and amongst these, we focused on three IgGs (A11-26, A11-37, A11-42) that could be purified in high yields (data not shown). By flow cytometry, all three IgGs showed good selectivity for integrin-α11/β1, as they bound robustly to C2C12-α11/β1 cell lines, but not to C2C12 cell lines engineered to over-express structurally related integrins α1/β1 and α2/β1 ( Figure 4a ). Quantitative flow cytometry showed tight and saturable binding of each antibody to CAF094-α11/β1 and C2C12-α11/β1 cell lines ( Figure 4b ) with EC 50 values in the sub-nanomolar range ( Table 1) .
Further corroboration of specificity for integrin-α11/β1 was provided by performing immunoprecipitation mass spectrometry (IP-MS) experiments with each IgG and CAF094-α11/β1 cells. Tandem mass spectra were searched against a human database to validate MS/MS protein identifications. Protein identifications were accepted if they could be established at greater than 99% probability based on identified peptides. After background filtering to remove keratin, immunoglobulin and cytoplasmic proteins, the highest peptide counts for all three IgGs were for integrin-α11 followed by integrin-β1 ( Figure 4c ).
We also used flow cytometry to assess epitope overlap by measuring the ability of various Fabs to block binding of each IgG to CAF094-α11/β1 cells ( Figure 4d ). As expected, preincubation of CAF094-α11/β1 cells with each Fab reduced subsequent binding of the cognate IgG. Moreover, Fabs A11-26 and A11-42 blocked binding of both A11-26 and A11-42 IgGs, whereas Ab A11-37 failed to compete for binding with the other IgGs tested. Taken together, these results showed that the three IgGs recognized cell-surface integrin-α11/β1 with high affinity and specificity, and Abs A11-26 and A11-42 likely bind to overlapping epitopes, whereas Ab 11-37 binds to a non-overlapping epitope.
Finally, we assessed whether the IgGs could inhibit integrin-α11/β1 function in a cellular context. The inhibitory assays were performed with standard reagents and growth media to measure the activity of the different IgGs in relevant physiological settings. As expected, based on the activities of the Fabs (Figure 2b) , each IgG was able to inhibit adhesion of C2C12-α11/β1 cells to immobilized collagen-I, indicating that they blocked binding of integrin-α11/β1 to collagen-I ( Figure 5a ). We further corroborated the inhibitory activity of the IgGs on integrin-α11/β1 function in a collagen-I gel contraction assay. 40, 41 In this assay, C2C12-α11/β1 cells and collagen-I were mixed to form polymerized lattice gels that were then floated with cell media in the presence of the different IgGs. After 24 hours, images of the polymerized gels were captured and gel surface areas were analyzed to assess integrin-mediated collagen-I gel contraction. We observed potent inhibition of collagen-I gel matrix contraction by the anti-integrin-α11/β1 IgGs (Figure 5b ). In both assays, IgGs A11-37 and A11-42 exhibited potencies in the sub-nanomolar range, whereas the potency of A11-26 was an order of magnitude weaker (Table 1) .
Altogether, our results showed that in situ phage display selections with naïve libraries were able to generate antiintegrin-α11/β1 Abs that targeted multiple epitopes on cellsurface antigen. Moreover, at least two distinct functional epitopes were identified that potently inhibited cell adhesion and gel contraction by blocking the interaction between integrin-α11/β1 and collagen-I.
Discussion
Over the years, many anti-integrin Abs have been developed using purified antigens and standard hybridoma methods, and numerous drugs have advanced into clinical development. [42] [43] [44] [45] [46] However in our selections with integrin-α11/β1, the immunodominant epitopes on the purified antigen appeared to be non-native epitopes that either do not exist or are not spatially accessible on the cell-surface form of the protein. Moreover, our results showed that cell-surface integrin-α11/β1 presents many epitopes that are either not present or are not immunodominant on purified antigen. These native epitopes may result from specific conformations, alternative glycosylation and/or additional protein-protein interactions that occur in the cell membrane, but are not recapitulated in the recombinant protein form.
Consequently, cell-surface selections proved crucial for generating a diverse panel of Abs targeting multiple epitopes, including some that do not block collagen binding and others that do. Our results raise the intriguing possibility that, despite extensive efforts to target integrins with Abs, the The abundance of each sequence in Fab-phage pools selected for binding to integrin-α11/β1 overexpressing cells (x-axis) is plotted versus the ratio of the abundance in pools selected for binding to cells overexpressing integrin-α11/β1 over pools selected for binding to cells not expressing integrin-α11/β1 (positive/negative, y-axis). Selections were performed with C2C12 mouse myoblast cells or human CAF cells in the presence of the indicated cation. Each circle represents a unique paratope (i.e., a unique combination of CDRs L3, H1, H2 and H3). The dashed lines define an upper-right quadrant that contains putative integrin-α11/β1-binding clones, defined arbitrarily as those occurring more than 100 times in the positive pool and being greater than two-fold enriched relative to the negative pool. Clones that were validated as specific integrin-α11/β1-binding Abs by ELISA screening (Figure 1 ) are shown as filled circles, colored as indicated. Each red circle represents the highest abundance and enrichment clone of a family cluster based on unique CDR L3 and H3 sequences (see Materials and Methods) that was not validated by ELISA, but is predicted to bind to integrin-α11/β1. The number in parentheses in the lower right quadrant is the number of unique potential integrin-α11/β1-binding clones in each upper-right quadrant, which is the sum of the validated (filled circles) and putative binders (red circles). (b) Venn diagrams for potential integrin-α11/β1-binding clones selected with the two different cell lines in the presence of Mg +2 , Ca +2 , or Mn +2 . The total unique clones are indicated at the bottom. (c) Venn diagram for total unique potential integrin-α11/β1-binding clones selected under the indicated cation conditions. predominant use of purified antigens may have left many native epitopes untapped. In turn, this may represent a great opportunity to revisit integrin biology and therapeutics with more comprehensive cell-based selection strategies. Moreover, the general methods presented here could be readily adapted to target other membrane proteins, including multi-pass integral membrane proteins for which efficient antibody generation remains a challenge.
Materials and methods
Cell lines
The human cancer-associated fibroblast (CAF094) cell lines (wildtype and overexpressing integrin-α11) 27 and the C2C12 mouse myoblast cell lines (wildtype and overexpressing integrin-α11, α1, or α2 in complex with the endogenously expressed integrin β1chain) were gifts from Dr. Ming Tsao at Princess Margaret Cancer Center, Toronto.
Antibody selections with recombinant antigen
Recombinant human integrin α11/β1 protein was obtained from a commercial vendor (R&D Systems, 6357-AB-050). As described by the vendor, the recombinant protein was expressed and purified in a secreted form from CHO cells and consisted of the complete extra-cellular domains of integrin-α11 and integrin-β1 fused at their C termini to complementary leucine zippers that formed heterodimers. Protein purity was verified by SDS-PAGE to be greater than 95% and functional activity was verified by detection of binding to collagen by ELISA. Phage pools representing synthetic antibody library-F 37 were cycled through multiple rounds of binding selections with the integrin α11/β1 protein immobilized on 96-well Maxisorp Immunoplates (Nunc), as described. 47, 48 After four rounds of selection, individual phage clones were isolated and grown in 96-deep-well plates with 2xYT medium supplemented with carbenicillin (Sigma-Aldrich) and M13K07 helper phage (New England Biolabs). The culture supernatants were diluted with one-tenth volume of 10x phosphatebuffered saline (PBS) and used directly in phage ELISAs to identify clones that bound to integrin α11/β1 with at least three-fold higher signals than to bovine serum albumin (BSA, Sigma-Aldrich), and these positive clones were subjected to DNA sequencing analysis.
Antibody selections with cellular antigen
Phage pools representing synthetic antibody library-F 37 were cycled through four rounds of binding selections using a parental cell line as the background depleting step, and an integrin-α11/β1 overexpressing cell line as the target selection step (Fig. S2C ). The adherent cell lines were suspended in PBS, 10 mM ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich). Ten million re-suspended cells (greater than 90% viability) were incubated under gentle rotation for 30 minutes at 4°C in 1 mL PBS, 1% BSA, 2 mM CaCl 2, 1 mM MgCl 2 or 0.5 mM MnCl 2 . Fab-phage (3 x 10 12 cfu) in 200 µL PBS, 1% BSA were added and the cells were incubated under gentle rotation for 2 hours at 4°C. In each round, Fab-phage were first incubated with the parental cell line, and following centrifugation to pellet the cells, supernatant containing unbound phage was collected. The collected supernatant was incubated with cells overexpressing integrin-α11/β1, the cells were pelleted by centrifugation. and the supernatant was discarded. The cells were washed four times with chilled PBS, 1% BSA, 2 mM CaCl 2, 1 mM MgCl 2 or 0.5 mM MnCl 2 . Bound phage were eluted from the cell pellet by resuspending the cells in 0.1 M hydrochloric acid, incubating for 10 minutes at room temperature, pelleting the cells by centrifugation, and collecting the supernatant containing eluted phage. After round 4, phage were eluted from both the parental cells and the cells overexpressing integrin-α11/β1 cells to enable NGS sequencing of both negative and positive pools. The eluted supernatant was neutralized with 11 M Tris buffer (Sigma-Aldrich) and cellular debris was removed by high-speed centrifugation. ) and quenched with 1.0 M phosphoric acid, and absorbance was determined at a wavelength of 450 nm. Positive binding clones were identified as those that produced at least three-fold greater signal on wells coated with integrin-α11/β1 compared to wells coated with BSA. For phage ELISAs to test binding to native antigen on cells, phage were added directly to the cellular media of CAF094 adherent cells (95-100% confluence) in tissue-culture-treated 96-well plates. After incubation for 45 minutes at room temperature, the plates were washed gently with PBS and the cells were fixed with 4% paraformaldehyde (Sigma-Aldrich). The cells were washed with PBS and incubated for 30 minutes with horseradish peroxidase/anti-M13 Ab conjugate (Sigma-Aldrich) in PBS buffer supplemented with 1% BSA. The plates were developed as described above. Clones were identified as positive if they produced at least two-fold greater signal on wells with integrin-α11/β1 overexpressing cells over parental cells. All positive clones were subjected to DNA sequence analysis.
Fab protein purification
Fab proteins were expressed in and purified from E. coli BL21 (ThermoFisher) with a FLAG epitope tag (amino acid sequence: DYKDDDDK) fused to the C-terminus of the light chain, as described. 49 Following expression, cells were harvested by centrifugation and cell pellets were flash-frozen using liquid nitrogen. The cell pellets were thawed, resuspended in lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 1 mg/ml lysozyme, 2 mM MgCl 2 , 10 units of benzonase), and incubated for 1 hour at 4°C. The lysates were cleared by centrifugation, applied to rProtein A-Sepharose columns (GE Healthcare), and washed with 10 column volumes of 50 mM Tris, 150 mM NaCl, pH 7.4. Fab protein was eluted with 100 mM phosphoric acid buffer, pH 2.5 (50 mM NaH 2 PO 4 , 140 mM NaCl, 100 mM H 3 PO 4 ) into a neutralizing buffer (1 M Tris, pH 8.0). The eluted Fab protein was buffer exchanged into PBS and concentrated using an Amicon-Ultra centrifugal filter unit (EMD Millipore). Fab protein was characterized for purity by SDS-PAGE gel chromatography and concentration was determined by spectrophotometry at an absorbance wavelength of 280 nm.
IgG purification
Full-length IgG proteins were expressed in mammalian cells as previously described. 47 Briefly, plasmids designed to express heavy and light chains were co-transfected into Expi293 cells (ThermoFisher) using the FuGENE® 6 Transfection Reagent kit (Promega), according to the manufacturer's instructions. After 5 days, cell culture media was harvested and applied to an rProtein-A affinity column (GE Healthcare version CYCLONE (2010.12.01.1)). Samples were searched against the Uniprot Human database (Downloaded May 1 2017, 20183 entries) assuming the digestion enzyme trypsin. Carbamidomethyl of cysteine was specified as a fixed modification. Deamidation of asparagine and glutamine were specified as variable modifications. Scaffold (version Scaffold_4.7.5, Proteome Software Inc., Portland, OR) was used to validate MS/MS based peptide and protein identifications. Peptide identifications were accepted if they could be established at greater than 95% probability. Peptide Probabilities from PEAKS Studio (Bioinformatic Solutions, Inc.) were assigned by the Peptide Prophet algorithm with Scaffold delta-mass correction. Peptide Probabilities from X! Tandem were assigned by the Scaffold Local FDR algorithm. Protein identifications were accepted if they could be established at greater than 99% probability and contained at least one identified peptide. Protein probabilities were assigned by the Protein Prophet algorithm. 50 Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. Proteins sharing significant peptide evidence were grouped into clusters.
Next-generation sequencing analysis
PCR amplicons were generated with Fab-phage pools as template, using forward and reverse primers that flanked CDRs L3 and H3, respectively. The primers included a 24 base-pair template annealing region followed by a 6-8 base-pair unique nucleotide barcode identifier and an Illumina universal adapter tag (PE1 or PE2 for the reverse or forward primer, respectively). The amplicons were isolated by gel electrophoresis followed by agarose gel extraction (Qiagen), and DNA concentrations were determined by spectrophotometry (BioteK). All amplicons were normalized, pooled and sequenced using a HiSeq 2500 instrument (Illumina) with 300 paired-end cycles. Besides PE1 and PE2 Illumina universal primers, the sequencing runs also included a custom primer that allowed for complete sequencing of CDRs H1 and H2. Thus, the three primer reads together provided complete sequence coverage of the four CDRs that were diversified in library F.
We analyzed two NGS replicates from each PCR sample. The sequencing reads for the two replicates were combined and then deconvoluted for each clone, and the three primer reads (PE1, PE2, and custom) were combined into a single sequence to derive the complete sequence. Sequences were filtered from sequencing errors using per base high quality score cutoff of Q = 30, which corresponds to 1:1000 of incorrect base call. 51 A total of 34,366,632 high quality nucleotide sequences (Table S1) were obtained, translated into amino acid sequences, and compared to the designed sequence repertoire of library F to filter out technical errors inherent to sequencing and PCR amplification. A total of 34,310,158 high quality amino acid sequences (Table S1) were obtained, and these were divided into positive and negative selection pools using the unique barcode identifiers encoded in the sequencing reads (Table S1 ). A positive pool was obtained for each integrin-α11/β1 overexpressing cell line (C2C12 and CAF094) under each cation condition (Ca +2 , Mg +2 , Mn +2 ). Similarly, a negative pool was obtained for the parental cell line (human integrin-α11 negative) under each cation condition. From each selection pool, hybridization errors and heteroduplex molecules that formed during the PCR hybridization were filtered using a frequency cutoff according to the maximum interclass inertia method of the Koenig-Huygens theorem. 52 In total, six pairs of positive/negative selection pools encompassing 25,556-139,612 unique amino acid sequences each were obtained (Table S1 ). The specificity score of each unique clone was calculated as its frequency fold-change in the positive pool over the negative pool, in order to discriminate specific binders from cross-reactive and nonspecific binders. In order to determine family clusters, each clone was grouped into highly homologous L3 and H3 sequences with other clones using a minimum homology cutoff of 75% sequence identity. 
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